Image 1
Trisenox Injection, Solution
Product Images NDC 63459-601
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Trisenox (NDC 63459-601). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Cephalon, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image 2
The text is a chart showing survival rates for newly-diagnosed acute promyelocytic leukemia (APL) patients treated with ATRA-arsenic trioxide and ATRA-chemotherapy over a period of 6 months. The x-axis represents months since diagnosis, and the y-axis represents the percentage of patients who are event-free (i.e., have not experienced disease recurrence or death). The chart shows a higher event-free survival rate for those receiving ATRA-arsenic trioxide compared to those receiving ATRA-chemotherapy. The chart also includes a table showing the number of patients at risk for each treatment group at various time intervals.*
Image 3
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
